- Home
- ZGN vs RCKT Comparison
ZGN vs RCKT Comparison
Compare ZGN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGN
- RCKT
- Stock Information
- Founded
- ZGN 1910
- RCKT 1999
- Country
- ZGN Italy
- RCKT United States
- Employees
- ZGN N/A
- RCKT N/A
- Industry
- ZGN Apparel
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- ZGN Consumer Discretionary
- RCKT Health Care
- Exchange
- ZGN Nasdaq
- RCKT Nasdaq
- Market Cap
- ZGN 2.0B
- RCKT 326.4M
- IPO Year
- ZGN N/A
- RCKT N/A
- Fundamental
- Price
- ZGN $9.15
- RCKT $2.95
- Analyst Decision
- ZGN Buy
- RCKT Buy
- Analyst Count
- ZGN 2
- RCKT 13
- Target Price
- ZGN $8.05
- RCKT $18.50
- AVG Volume (30 Days)
- ZGN 1.9M
- RCKT 4.3M
- Earning Date
- ZGN 03-27-2025
- RCKT 08-04-2025
- Dividend Yield
- ZGN 1.54%
- RCKT N/A
- EPS Growth
- ZGN N/A
- RCKT N/A
- EPS
- ZGN 0.31
- RCKT N/A
- Revenue
- ZGN $2,015,371,157.00
- RCKT N/A
- Revenue This Year
- ZGN $0.74
- RCKT N/A
- Revenue Next Year
- ZGN $4.74
- RCKT N/A
- P/E Ratio
- ZGN $29.46
- RCKT N/A
- Revenue Growth
- ZGN 2.21
- RCKT N/A
- 52 Week Low
- ZGN $6.05
- RCKT $2.19
- 52 Week High
- ZGN $11.69
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- ZGN 63.83
- RCKT 41.69
- Support Level
- ZGN $8.24
- RCKT $2.40
- Resistance Level
- ZGN $8.99
- RCKT $2.70
- Average True Range (ATR)
- ZGN 0.32
- RCKT 0.21
- MACD
- ZGN -0.01
- RCKT 0.15
- Stochastic Oscillator
- ZGN 86.32
- RCKT 73.53
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.